Skip to main content
Top
Published in: Endocrine Pathology 2/2016

01-06-2016

Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF V600E Harboring Pediatric Papillary Thyroid Carcinomas

Authors: Semen Onder, Sule Ozturk Sari, Gulcin Yegen, Ismail Cem Sormaz, Ismail Yilmaz, Sukran Poyrazoglu, Yasemin Sanlı, Yasemin Giles Senyurek, Yersu Kapran, Ozgur Mete

Published in: Endocrine Pathology | Issue 2/2016

Login to get access

Abstract

This study is aimed to investigate the BRAF V600E and TERT promoter mutation profile of 50 pediatric papillary thyroid carcinomas (PTCs) to refine their clinicopathological correlates. The median age at the time of surgery was 16 years (range, 6–18). No TERT promoter mutations were identified in this series. The BRAF V600E mutation was present in 15 (30 %) tumors. From genotype-histologic variant correlation perspective, 13 of 24 classic variant PTCs and 2 of 7 diffuse sclerosing variant PTCs were found to harbor BRAF V600E mutation. One cribriform-morular variant, 3 solid variant, and 15 follicular variant PTCs were BRAF wild type. While tumors with distant metastasis were BRAF wild type, two of five tumors with extrathyroidal extension (ETE) harbored BRAF V600E mutation. Nine of 15 BRAF V600E harboring tumors had central lymph node metastases. There was no significant correlation with BRAF V600E mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis. An adverse correlation between BRAF V600E mutation and disease-free survival (DFS) was noted in the entire cohort; however, the predictive value of BRAF V600E mutation disappeared within the group of tumors displaying classic architecture as well as classic variant PTCs. The present cohort identifies that the classic architecture with multicentricity and local recurrence are correlates of BRAF V600E harboring pediatric PTCs. While the small size of this cohort is one of the limitations, neither the BRAF mutation status nor the classic tumor architecture does seem to be an independent prognosticator of DFS in this series. Evidence also suggests that TERT promoter mutations do not seem to play a major role in the pathogenesis of pediatric PTCs.
Literature
1.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004.
2.
go back to reference Cordioli MI, Moraes L, Cury AN, Cerutti JM. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma? Endocr Relat Cancer 22: R311-324, 2015.CrossRefPubMed Cordioli MI, Moraes L, Cury AN, Cerutti JM. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma? Endocr Relat Cancer 22: R311-324, 2015.CrossRefPubMed
3.
go back to reference Kiratli PO, Volkan-Salanci B, Günay EC, Varan A, Akyüz C, Büyükpamukçu M. Thyroid cancer in pediatric age group: an institutional experience and review of the literature. J Pediatr Hematol Oncol 35: 93–97, 2013.CrossRefPubMed Kiratli PO, Volkan-Salanci B, Günay EC, Varan A, Akyüz C, Büyükpamukçu M. Thyroid cancer in pediatric age group: an institutional experience and review of the literature. J Pediatr Hematol Oncol 35: 93–97, 2013.CrossRefPubMed
4.
go back to reference Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001–2009. Pediatrics 134: E945-955, 2014.CrossRefPubMedPubMedCentral Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001–2009. Pediatrics 134: E945-955, 2014.CrossRefPubMedPubMedCentral
5.
go back to reference Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159: 676–690, 2014. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159: 676–690, 2014.
6.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26: 1–133, 2016.CrossRefPubMed Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26: 1–133, 2016.CrossRefPubMed
7.
go back to reference Jarzab B, Handkiewicz-Junak D. Differentiated thyroid cancer in children and adults: same or distinct disease? Hormones 6: 200–209, 2007.PubMed Jarzab B, Handkiewicz-Junak D. Differentiated thyroid cancer in children and adults: same or distinct disease? Hormones 6: 200–209, 2007.PubMed
8.
go back to reference Francis G, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti J, Dinauer CA, Hamilton JK, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid 25:716–759, 2015.CrossRefPubMed Francis G, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti J, Dinauer CA, Hamilton JK, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid 25:716–759, 2015.CrossRefPubMed
9.
go back to reference Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroid cancer. Curr Opin Oncol 28: 37–42, 2016.CrossRefPubMed Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroid cancer. Curr Opin Oncol 28: 37–42, 2016.CrossRefPubMed
10.
go back to reference Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34: 1192–1202, 2010.CrossRefPubMed Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34: 1192–1202, 2010.CrossRefPubMed
11.
go back to reference Ballester LY, Sarabia SF, Sayeed H, Patel N, Baalwa J, Athanassaki I, Hernandez JA, Fang E, Quintanilla NM, Roy A, López-Terrada DH. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions. Pediatr Dev Pathol. 2015 Ballester LY, Sarabia SF, Sayeed H, Patel N, Baalwa J, Athanassaki I, Hernandez JA, Fang E, Quintanilla NM, Roy A, López-Terrada DH. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions. Pediatr Dev Pathol. 2015
12.
go back to reference Ngeow J, Eng C. TERT and BRAF in thyroid cancer: teaming up for trouble. J Clin Oncol 32: 2683–2684, 2014.CrossRefPubMed Ngeow J, Eng C. TERT and BRAF in thyroid cancer: teaming up for trouble. J Clin Oncol 32: 2683–2684, 2014.CrossRefPubMed
13.
go back to reference Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32: 2718–2726, 2014.CrossRefPubMedPubMedCentral Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32: 2718–2726, 2014.CrossRefPubMedPubMedCentral
14.
go back to reference Tavares C, Melo M, Cameselle Teijeiro JM, Soares P, Sobrinho-Simoes M. Genetic predictors of thyroid cancer outcome. Eur J Endocrinol. 2015. Tavares C, Melo M, Cameselle Teijeiro JM, Soares P, Sobrinho-Simoes M. Genetic predictors of thyroid cancer outcome. Eur J Endocrinol. 2015.
15.
go back to reference Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P. Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? J Clin Oncol 33: 667–668, 2015.CrossRefPubMed Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P. Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? J Clin Oncol 33: 667–668, 2015.CrossRefPubMed
16.
go back to reference Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T, Grigsby PW. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 61: 1168–1172, 2014.CrossRefPubMed Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T, Grigsby PW. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 61: 1168–1172, 2014.CrossRefPubMed
17.
go back to reference Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118: 1764–1773, 2012.CrossRefPubMed Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118: 1764–1773, 2012.CrossRefPubMed
18.
go back to reference Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 32: 86–93, 2010.CrossRef Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 32: 86–93, 2010.CrossRef
19.
go back to reference Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253: 854–860, 2009.CrossRefPubMed Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253: 854–860, 2009.CrossRefPubMed
20.
go back to reference Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L. Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 18: 3566–3571, 2011.CrossRefPubMed Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L. Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 18: 3566–3571, 2011.CrossRefPubMed
21.
go back to reference Liu X, Bishop J, Shan Y, Pai S, Lui D, Murugan AK, Sun H, El-Naggar AK& Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20: 603–610, 2013.CrossRefPubMedPubMedCentral Liu X, Bishop J, Shan Y, Pai S, Lui D, Murugan AK, Sun H, El-Naggar AK& Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20: 603–610, 2013.CrossRefPubMedPubMedCentral
22.
go back to reference Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P. Frequency of TERT promoter mutations in human cancers. Nat Commun 4: 2185, 2013.CrossRefPubMed Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P. Frequency of TERT promoter mutations in human cancers. Nat Commun 4: 2185, 2013.CrossRefPubMed
23.
go back to reference Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33: 4978–4984, 2014.CrossRefPubMed Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33: 4978–4984, 2014.CrossRefPubMed
24.
go back to reference Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Maximo V, Sobrinho-Simoes M, Soares P. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99: E754-765, 2014.CrossRefPubMedPubMedCentral Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Maximo V, Sobrinho-Simoes M, Soares P. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99: E754-765, 2014.CrossRefPubMedPubMedCentral
25.
go back to reference Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99: E1130-1136, 2014.CrossRefPubMedPubMedCentral Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99: E1130-1136, 2014.CrossRefPubMedPubMedCentral
26.
go back to reference Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M. Prognostic biomarkers in thyroid cancer. Virchows Arch 464: 333–346, 2014.CrossRefPubMed Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M. Prognostic biomarkers in thyroid cancer. Virchows Arch 464: 333–346, 2014.CrossRefPubMed
27.
go back to reference Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 124: E389–393, 2014.CrossRefPubMed Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 124: E389–393, 2014.CrossRefPubMed
28.
go back to reference Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016 Jan 19. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016 Jan 19.
29.
go back to reference Alzahrani AS, Qasem E, Murugan AK, Al-Hindi HN, AlKhafaji D, Almohanna M, Xing M, Alhomaidah D, AlSwailem M. Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer. Thyroid. 2016 Jan 21. Alzahrani AS, Qasem E, Murugan AK, Al-Hindi HN, AlKhafaji D, Almohanna M, Xing M, Alhomaidah D, AlSwailem M. Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer. Thyroid. 2016 Jan 21.
30.
go back to reference Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS. Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. Thyroid. 2016 Jan 7. Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS. Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. Thyroid. 2016 Jan 7.
31.
go back to reference Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Tuttle RM, Francis G. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15(4): 320–325, 2005.CrossRefPubMed Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Tuttle RM, Francis G. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15(4): 320–325, 2005.CrossRefPubMed
32.
go back to reference Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 18: 898–902, 2005.CrossRefPubMed Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 18: 898–902, 2005.CrossRefPubMed
33.
go back to reference Yamashita S, Saenko V. Mechanisms of Disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3: 422–499, 2007.CrossRefPubMed Yamashita S, Saenko V. Mechanisms of Disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3: 422–499, 2007.CrossRefPubMed
34.
go back to reference Al-Qahtani KH, Tunio MA, Al Asiri M, Aljohani NJ, Bayoumi Y, Riaz K, AlShakweer W. Clinicopathological features and treatment outcomes of differentiated thyroid cancer in Saudi children and adults. J Otolaryngol Head Neck Surg 44:48, 2015.CrossRefPubMedPubMedCentral Al-Qahtani KH, Tunio MA, Al Asiri M, Aljohani NJ, Bayoumi Y, Riaz K, AlShakweer W. Clinicopathological features and treatment outcomes of differentiated thyroid cancer in Saudi children and adults. J Otolaryngol Head Neck Surg 44:48, 2015.CrossRefPubMedPubMedCentral
35.
go back to reference Silva-Vieira M, Santos R, Leite V, Limbert E. Review of clinical and pathological features of 93 cases of well-differentiated thyroid carcinoma in pediatric age at the Lisbon Centre of the Portuguese Institute of Oncology between 1964 and 2006. Int J Pediatr Otorhinolaryngol 79: 1324–1349, 2015.CrossRefPubMed Silva-Vieira M, Santos R, Leite V, Limbert E. Review of clinical and pathological features of 93 cases of well-differentiated thyroid carcinoma in pediatric age at the Lisbon Centre of the Portuguese Institute of Oncology between 1964 and 2006. Int J Pediatr Otorhinolaryngol 79: 1324–1349, 2015.CrossRefPubMed
36.
go back to reference Lee YA, Jung HW, Kim HY, Choi H, Kim HY, Hah JH, Park do J, Chung JK, Yang SW, Shin CH, Park YJ. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab 100: 1619–1629, 2015.CrossRefPubMed Lee YA, Jung HW, Kim HY, Choi H, Kim HY, Hah JH, Park do J, Chung JK, Yang SW, Shin CH, Park YJ. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab 100: 1619–1629, 2015.CrossRefPubMed
37.
go back to reference Lerner J, Goldfarb M. Follicular variant papillary thyroid carcinoma in a pediatric population. Pediatr Blood Cancer 62: 1942–1946, 2015.CrossRefPubMed Lerner J, Goldfarb M. Follicular variant papillary thyroid carcinoma in a pediatric population. Pediatr Blood Cancer 62: 1942–1946, 2015.CrossRefPubMed
38.
go back to reference Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, Chung JH, Ki CS, Kim SW. Diffuse sclerosing variant of papillary thyroid carcinoma: Major genetic alterations and prognostic implications. Histopathology. 2015 Nov 14. Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, Chung JH, Ki CS, Kim SW. Diffuse sclerosing variant of papillary thyroid carcinoma: Major genetic alterations and prognostic implications. Histopathology. 2015 Nov 14.
39.
go back to reference Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O’Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, O’Toole SA, Sywak M, Gill AJ. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39: 652–659, 2015.CrossRefPubMedPubMedCentral Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O’Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, O’Toole SA, Sywak M, Gill AJ. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39: 652–659, 2015.CrossRefPubMedPubMedCentral
Metadata
Title
Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF V600E Harboring Pediatric Papillary Thyroid Carcinomas
Authors
Semen Onder
Sule Ozturk Sari
Gulcin Yegen
Ismail Cem Sormaz
Ismail Yilmaz
Sukran Poyrazoglu
Yasemin Sanlı
Yasemin Giles Senyurek
Yersu Kapran
Ozgur Mete
Publication date
01-06-2016
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2016
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9420-0

Other articles of this Issue 2/2016

Endocrine Pathology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine